Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ceftolozane/tazobactam (Zerbaxa) is an antibiotic indicated for complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP).
• The information was derived from 17 systematic reviews and meta-analyses.
• Zerbaxa shows comparable efficacy to other antibiotics like ceftazidime-avibactam, imipenem-cilastatin-relebactam, and cefiderocol in treating Pseudomonas aeruginosa infections with similar safety profiles.
• For cIAI, Zerbaxa has shown comparable clinical cure rates to carbapenems such as meropenem with a similar risk of adverse events; however, cefepime plus metronidazole ranked highest in terms of efficacy and safety.
• Limited data suggest favorable results for neonatal multi-drug-resistant Gram-negative infections treated with Zerbaxa regarding both efficacy and safety.
• In nosocomial pneumonia cases, including HABP/VABP, Zerbaxa demonstrated non-inferiority compared to other antibiotics concerning clinical response and mortality outcomes while maintaining a comparable rate of adverse events.
• Higher clinical cure rates were observed when using Zerbaxa for UTIs compared to piperacillin/tazobactam without significant differences in serious adverse event incidence.
• Favorable outcomes have been noted in bloodstream infection treatments involving multi-drug-resistant (MDR) pathogens using Zerbaxa; further studies are recommended based on these initial findings.